No Data
China antibody-B (03681): Director Liu Wenyi resigns as non-executive director
China Antibody-B (03681) announced that Liu Wenyi has resigned as a non-executive director, effective September 2024...
SINOMAB BIO-B: Interim Report 2024
Some biomedical stocks rise, Akeso (09926) rises 13.9%, institutions indicate that the sector's fundamentals are gradually bottoming out and stabilizing.
Golden Finance News | Some biomedical stocks rose, with Akeso (09926) up 13.9%, Sanpower Medical (02257) up 5.47%, China Antibody (03681) up 4.35%, GL Pharm (01672) up 4.12%, Viva Biotech (01873) up 3.45%, Wuxi AppTec (02359) up 2.6%, Wuxi Bio (02269) up 1.27%. China Post Securities expressed that the overall revenue growth rate of the biomedical sector compared to the same period last year is -1.26%, lower than Q1 growth rate, mainly due to vaccines (-32.75%), and CXO (-9.45%).
Have Insiders Sold SinoMab BioScience Shares Recently?
SinoMab BioScience's H1 Loss Narrows as Revenue Rises; Shares Fall 15%
China Antibody-B (03681) released its interim performance with a revenue of 2.026 million yuan, a year-on-year increase of 48.4%.
China Antibody-B (03681) released its six-month performance ending on June 30, 2024, with revenue of 202.6 million...
No Data
No Data